HC Wainwright & Co. Maintains Buy on Harpoon Therapeutics, Raises Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a 'Buy' rating on Harpoon Therapeutics (NASDAQ:HARP) and raises the price target from $4.5 to $7.5.
September 14, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The 'Buy' rating maintained by HC Wainwright & Co. and the raised price target could potentially lead to an increase in Harpoon Therapeutics' stock price.
Analyst ratings and price targets can significantly influence investor sentiment. The maintained 'Buy' rating and increased price target from HC Wainwright & Co. indicates a positive outlook for Harpoon Therapeutics, which could lead to increased demand for the stock and a potential rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100